Robert L. Shepard
Impact in
- Oncology top 2%
- Drug Transport and Resistance Mechanisms
- Geriatrics and Gerontology top 5%
- Sirtuins and Resveratrol in Medicine
Papers in
- Oncology 21
- Drug Transport and Resistance Mechanisms 17
-
- Histone Deacetylase Inhibitors Research 3
- Co-authors
- Anne H. Dantzig (25 shared papers)James J. Starling (6 shared papers)Susan E. Pratt (9 shared papers)Jin Cao (3 shared papers)Steven Wrighton (6 shared papers)Mark A. Winter (7 shared papers)William J. Ehlhardt (2 shared papers)Todd M. Baughman (2 shared papers)
- Journals
- Molecular Pharmacology (4 papers)Journal of Biological Chemistry (4 papers)Clinical Cancer Research (3 papers)Molecular Cancer Therapeutics (2 papers)Biochemical Pharmacology (2 papers)
- Partner nations
- United StatesCanadaUnited Kingdom
In The Last Decade
Robert L. Shepard
33 papers receiving 2.0k citations
Peers
Comparison fields: 5 of 108
- Oncology 1.3k
- Geriatrics and Gerontology 87
- Pharmacology 207
- Pediatrics, Perinatology and Child Health 407
- Infectious Diseases 302
Countries citing papers authored by Robert L. Shepard
This map shows the geographic impact of Robert L. Shepard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert L. Shepard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert L. Shepard more than expected).
Fields of papers citing papers by Robert L. Shepard
This network shows the impact of papers produced by Robert L. Shepard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert L. Shepard. The network helps show where Robert L. Shepard may publish in the future.
Co-authors
The 25 scholars most cited alongside Robert L. Shepard, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 36 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. | 1996 | 298 |
| 2 | 2005 | 191 | |
| 3 | 1994 | 164 | |
| 4 | 2002 | 161 | |
| 5 | 1999 | 154 | |
| 6 | 2002 | 145 | |
| 7 | 2012 | 138 | |
| 8 | 2002 | 115 | |
| 9 | 2013 | 92 | |
| 10 | 1997 | 75 | |
| 11 | 2003 | 63 | |
| 12 | 1988 | 52 | |
| 13 | 2002 | 52 | |
| 14 | 1998 | 49 | |
| 15 | 2015 | 40 | |
| 16 | 2002 | 40 | |
| 17 | 2005 | 38 | |
| 18 | 2003 | 32 | |
| 19 | 2002 | 31 | |
| 20 | 1996 | 30 |
About Robert L. Shepard
Robert L. Shepard is a scholar working on Oncology, Molecular Biology, Pediatrics, Perinatology and Child Health, Infectious Diseases and Physiology, having authored 36 papers that have together received 2.1k indexed citations. Recurring topics across this work include Drug Transport and Resistance Mechanisms (17 papers), Pharmacological Effects and Toxicity Studies (6 papers), HIV/AIDS drug development and treatment (5 papers), Adenosine and Purinergic Signaling (4 papers), Amino Acid Enzymes and Metabolism (3 papers), Computational Drug Discovery Methods (3 papers), Histone Deacetylase Inhibitors Research (3 papers) and Cholinesterase and Neurodegenerative Diseases (2 papers). The work is most often cited by research in Oncology (1.3k citations), Geriatrics and Gerontology (87 citations), Pharmacology (207 citations), Pediatrics, Perinatology and Child Health (407 citations) and Infectious Diseases (302 citations). Robert L. Shepard has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include Anne H. Dantzig, James J. Starling, Susan E. Pratt, Jin Cao, Steven Wrighton, Mark A. Winter, William J. Ehlhardt, Todd M. Baughman, William L. Perry and Linda B. Tabas. Their work appears in journals such as Molecular Pharmacology, Journal of Biological Chemistry, Clinical Cancer Research, Molecular Cancer Therapeutics and Biochemical Pharmacology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.